← Back to Search

OCT Angiography for Retinopathy (OCTA-RVD Trial)

N/A
Recruiting
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

OCTA-RVD Trial Summary

This trial will help better define when someone with retinal vascular disease is progressing or regressing so that treatment can be more accurately given.

Who is the study for?
This trial is for individuals with retinal vascular diseases like diabetic retinopathy or retinal vein occlusion, as well as those with high blood pressure that may affect the retina. Participants should be able to undergo regular imaging tests to track changes in their eye condition over time.Check my eligibility
What is being tested?
The study is testing different eye imaging techniques: Swept-Source OCT Angiography, Spectral-Domain OCT Angiography, Fundus Imaging, and Axial Length Measurement Device. It aims to observe how these methods can detect changes in the retina due to disease progression or treatment effects.See study design
What are the potential side effects?
Since this trial involves non-invasive imaging of the eyes, side effects are minimal but may include temporary discomfort from bright lights during imaging or mild eye strain.

OCTA-RVD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Correlation of Imaging

OCTA-RVD Trial Design

4Treatment groups
Experimental Treatment
Group I: Hypertension OnlyExperimental Treatment4 Interventions
Subjects in this group only have hypertension with or without ocular pathology related to hypertension. Some subjects in this arm may undergo retinal vascular reactivity assessments.
Group II: Diabetics with and without Diabetic Retinopathy OnlyExperimental Treatment4 Interventions
Subjects in this group only have diabetes with or without diabetic retinopathy. Some subjects in this arm will undergo retinal vascular reactivity assessments.
Group III: Diabetics w/ or w/o Diabetic Retinopathy & HypertensionExperimental Treatment4 Interventions
Subjects in this group have diabetes with or without diabetic retinopathy and hypertension with or without ocular pathology related to hypertension. Some subjects in this arm may undergo retinal vascular reactivity assessments.
Group IV: ControlsExperimental Treatment4 Interventions
Subjects in this group do not have any ocular pathology and are also not hypertensive. Some subjects in this arm will undergo retinal vascular reactivity assessments.

Find a Location

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor
2,245 Previous Clinical Trials
14,815,456 Total Patients Enrolled
National Eye Institute (NEI)NIH
546 Previous Clinical Trials
1,400,944 Total Patients Enrolled

Media Library

Controls Clinical Trial Eligibility Overview. Trial Name: NCT04505618 — N/A
Retinopathy Research Study Groups: Controls, Diabetics with and without Diabetic Retinopathy Only, Diabetics w/ or w/o Diabetic Retinopathy & Hypertension, Hypertension Only
Retinopathy Clinical Trial 2023: Controls Highlights & Side Effects. Trial Name: NCT04505618 — N/A
Controls 2023 Treatment Timeline for Medical Study. Trial Name: NCT04505618 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the trial include minors within its parameters?

"As per the eligibility requirements, participants between 18 and 99 years old are qualified to take part in this clinical trial. There are an additional 13 trials specifically for minors and 219 studies available for adults over 65."

Answered by AI

What type of patient can best benefit from this trial?

"The prerequisites for entering this clinical trial are that prospective patients must possess diabetic retinopathy and be aged between 18 to 99 years old. The goal of the research is to recruit 1050 individuals."

Answered by AI

Are there any vacancies available in the experiment?

"This medical research programme is enrolling participants, as per the latest updates on clinicaltrials.gov. It was first announced in October 2019 and was revised last August 2022."

Answered by AI

What is the cap on participant numbers for this experiment?

"Yes, the details listed on clinicaltrials.gov verify that this research study is actively enrolling participants. This trial was initially posted in October 2019 and edited for the last time in August 2022. It requires 1050 individuals from 2 medical facilities to participate."

Answered by AI
~216 spots leftby Jun 2025